艾美赛珠单抗在加拿大血友病A患者中的长期应用经验:CBDR登记研究
基于加拿大出血性疾病登记处(CBDR)的观察性队列研究,纳入2018年至2023年接受至少1剂艾美赛珠单抗的710例先天性血友病A患者,评估长期安全性和有效性。
要点
- 艾美赛珠单抗预防治疗使平均ABR从1.00降至0.47,降幅约53%。
- 中位随访549天,61.8%患者无出血记录,出血控制可持续长达5年。
- 34例不良事件包括2例血栓事件,安全性特征与既往报告一致。
核心结论
- 艾美赛珠单抗在先天性血友病A患者中长期应用可显著降低出血率并维持出血控制,安全性特征与既往报告一致。
研究设计与样本
- 采用负二项回归模型进行患者内用药前后所有报告出血的年化出血率(ABR)比较。
主要发现
- 710例患者中539例(75.9%)艾美赛珠单抗暴露超过1年。
- 中位随访549天(第一至第三四分位数374-690天),439例(61.8%)无出血记录。
- 观察期间共记录34例不良事件,包括2例血栓事件(1例与艾美赛珠单抗不太可能相关;1例可能与既往使用依他凝血素α和/或既往艾美赛珠单抗相关,并与中心静脉通路装置相关)。
- 在长达5年的随访期内观察到出血显著减少和持续的出血控制。
临床怎么用
- 艾美赛珠单抗预防治疗可用于先天性血友病A患者,长期应用可降低出血频率并维持出血控制。
- 用药期间需关注血栓事件风险,尤其是存在中心静脉通路装置或既往使用依他凝血素α的患者。
局限性
- 观察性研究设计,无法完全排除混杂因素。
- 需继续随访以更精确量化长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emicizumab prophylaxis has been approved in Canada for the prevention or reduction of bleeding episodes in people with congenital hemophilia A (PwHA). Using routinely collected health data from the Canadian Bleeding Disorders Registry (CBDR), this observational cohort study aimed to evaluate the long-term safety and effectiveness of emicizumab in PwHA. Deidentified data from the CBDR were collected for PwHA who had received ≥1 dose of emicizumab from 2018 up to 31 December 2023. Intrapatient comparisons of annualized bleeding rates (ABRs) for all reported bleeds before and after emicizumab were performed using a negative binomial regression model. Overall, 710 PwHA received ≥1 emicizumab dose, and 539 (75.9%) had >1 year of emicizumab exposure. During the observational period, the safety profile was in keeping with previous reports; 34 adverse events were observed, including 2 thrombotic events (1 unlikely related to emicizumab; 1 probably related to previous use of eptacog alfa and/or possibly related to previous emicizumab, and associated with a central venous access device). Over a median (first to third quartiles) follow-up time of 549 (374-690) days, 439 (61.8%) PwHA had no recorded bleeds. Mean ABR decreased from 1.00 (95% confidence interval [CI], 0.87-1.14) before emicizumab to 0.47 (95% CI, 0.40-0.55) after emicizumab (rate ratio, 0.47 [95% CI, 0.41-0.55]; P< .001). A notable decrease in bleeds and sustained bleed control were observed in this population for up to a 5-year follow-up period. Continued follow-up will allow for greater quantification of this impact over time, providing valuable information to health care practitioners and regulatory authorities.
引用
- Iorio A, Germini F, Ibrahim Q, et al. Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry. Blood Adv. 2026. PMID: 42466987. doi:10.1182/bloodadvances.2025019430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。